Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:06 AM
Ignite Modification Date:
2025-12-25 @ 2:06 AM
NCT ID:
NCT01729260
Eligibility Criteria:
Inclusion Criteria:
1. Patients must have histologically confirmed newly diagnosed high-grade glioma(WHO Grade III or IV)
2. Age ≥18 years
3. Karnofsky Performance Score (KPS) ≥ 60%
4. Life expectancy greater than 12 weeks
5. Patients must have adequate organ and marrow function
6. Completed \>80% of the prescribed radiation therapy and concurrent temozolomide according to the Stupp regimen without grade 3 or 4 hematologic toxicity
7. Patients may have received Gliadel during surgery
8. Ability to swallow pills and keep medication record
9. women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation.
10. Ability to understand and willingness to sign a written informed consent document
11. Be able to comply with treatment plan, study procedures and follow-up examinations
Exclusion Criteria:
1. Patients must not have received prior therapy other than standard chemoradiation according to Stupp et al and Gliadel.
2. Patients may not be receiving any other investigational agents while on study
3. Patients who have known allergy to mebendazole or benzimidazole
4. Patients who have previously had a severe side effect, such as agranulocytosis and neutropenia, in conjunction with previous mebendazole or benzimidazole class drug for a parasitic infection
5. Patients who are taking metronidazole and cannot be safely moved to a different antibiotic greater than 7 days prior to starting mebendazole therapy
6. Patients who have taken any benzimidazole (ABZ, flubendazole, thiabendazole, fenbendazole, triclabendazole, etc.) within the last 3 months
7. Patients who are taking any anti-convulsant medication that interferes with the cytochrome P450 pathway (e.g. phenytoin, phenobarbital, carbamazepine, etc.)
8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, chronic hepatitis, acute hepatitis, or psychiatric illness/social situation that would limit compliance with study requirements
9. Pregnant women are excluded
10. Patients with human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive; or with a history of chronic active hepatitis or cirrhosis
11. Patients with a history of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with the study participation or investigational product administration or may interfere with the interpretation of the results
12. Patients who are not available for follow-up assessments or unable to comply with study requirements
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01729260
Study Brief:
Protocol Section:
NCT01729260